BioCentriq, Inc. and panCELLa, a Pluristyx Company, signed a research agreement to evaluate the ability of panCELLa’s genetically engineered, induced Pluripotent Stem Cell (iPSC)-derived, feeder cells to activate and positively impact the expansion rate, total yield, and potency of manufactured NK cells. BioCentriq, a CDMO focused exclusively on accelerating the development and manufacturing of cell therapies, aims to expand and cryopreserve the feeder cell bank for use as a reagent to ...